Preemptive therapy in the prevention of cytomegalovirus disease in high- and low-risk heart transplant recipients.

Cytomegalovirus (CMV) infection remains a major complication in recipients of solid organ transplantation. Based on available evidence, most centers are committed to an aggressive strategy, especially in high-risk patients, consisting of the use of universal prophylaxis in the posttransplantation period of maximum risk (3 months). In seropositive recipients there is no ideal model for prevention, although there is more acceptance in the international community for preemptive therapy.